About
insitro is a machine learning-driven drug discovery and development company that combines high-throughput cellular data with human clinical and genomic data to build predictive models of disease, advancing its own pipeline (ALS, liver disease, oncology, metabolic disease) and partnering with large pharma.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- insitro
insitro is a machine learning-driven drug discovery and development company that combines high-throughput cellular data with human clinical and genomic data to build predictive models of disease, advancing its own pipeline (ALS, liver disease, oncology, metabolic disease) and partnering with large pharma.
$400M
$400M
United States
BusinessLatest roundTotal raisedDate- LifeMine Therapeutics
A clinical-stage precision drug discovery company based on fungal genome mining, developing novel therapies in transplantation and immunology.
Series D+ · $558M · 2026-08
$558M - Tahoe Therapeutics
Develops large-scale single-cell datasets to train AI models of human cells for drug discovery
Undisclosed · $30M · 2025-08
$30M - Apricity Health
Tech-driven virtual oncology care platform plus Dynamic Precision real-world data drug discovery engine, integrating patient-reported outcomes, EHRs and genomic data; serves cancer patients and care teams, academic cancer centers and pharma companies, using longitudinal patient data to find druggable adaptive resistance mechanisms and companion biomarkers.
—
China
BusinessLatest roundTotal raisedDate- 元示科技
AI Virtual Cell (AIVC): a raw biological data engine and general-purpose cell foundation model forming a life sciences base, with an ultra-high-throughput cell perturbation platform to predict drug perturbation effects across cell types, for early-stage drug discovery at pharmaceutical companies and research institutions.
Angel · 2026-10
— - Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M
Europe
BusinessLatest roundTotal raisedDate- Basecamp Research
Trains the EDEN foundation model on proprietary biodiversity genomic data and uses AI to design proteins and in vivo cell therapies
Series C · $200M · 2026-09
$200M - Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B - Rivercell
In-house automated wet lab generating large-scale single-cell perturbation data to train "AI virtual cell" models that predict human cell responses to drugs and genetic changes
Seed · 2026-10
—
Other / unspecified
BusinessLatest roundTotal raisedDate- Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
— - Miles Wang 新公司
Develops AI models for drug discovery
— - 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.